Roche

F. Hoffmann-La Roche AG, Basel, Switzerland

General Information

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and conditions and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. The Neuroscience group in Roche has expertise in many areas, including autism spectrum disorder (ASD), Alzheimer’s disease, schizophrenia, depression, and imaging which spans from discovery where Roche scientists have made major advancements in identifying pathways involved in ASD, schizophrenia and depression to the clinic where innovative new first-in-class medications are being developed for these major psychiatric disorders.

Role in AIMS-2-TRIALS

The Neuroscience group at Roche is committed to contribute to the success of AIMS-2-TRIALS. As part of the project Roche aims to bring experience in designing meaningful trials to understand meaningful endpoints for people with ASD. Through the broad collaboration we hope to be able to understand the wants and needs of the community more broadly, so that all groups can develop meaningful approaches to help people with ASD.

Will Spooren

Roche Lead

Will Spooren

Will Spooren

 Head Neurodevelopmental disorders (NDD) Section

Elizabeth Ashford

Elizabeth Ashford

Operations Program Leader

Barbara Biemans

Barbara Biemans

 Principal Scientist

Christopher Chatham

Christopher Chatham

 Biomarker Experimental Medicine Leader

Lindsay Ham

Lindsay Ham

 Regulatory Affairs Specialist

Jörg Hipp

Jörg Hipp

Principal Scientist 

Denise Morgan

Denise Morgan

 Regulatory Affairs Specialist

Lorraine Murtagh

Lorraine Murtagh

 NDD Leader

Alma Rubio

Alma Rubio

Head of Patient Partnership 

Kevin Sanders

Kevin Sanders

 Global Development Lead – Autism 

Lisa Shafe

Lisa Shafe

 Clinical Programme Leader

Jeroen Tinbergen

Jeroen Tinbergen

 

Daniel Umbricht

Daniel Umbricht

Distinguished Scientist 

Adrian Ward

Adrian Ward

 International Health Policy Leader